Neuphoria Therapeutics (NEUP) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
18 Sep, 2026Executive summary
Proxy materials for the annual stockholders' meeting are available online, with voting instructions provided for ease of access and participation.
The annual meeting is scheduled for November 2, 2026, and shareholders are encouraged to review all proxy materials before voting.
Voting matters and shareholder proposals
Shareholders are notified of items to be voted on at the annual meeting, with details available in the proxy materials.
Voting can be completed online, and shareholders may request paper copies of materials at no charge.
Shareholder rights and capital structure
Shareholders are given the option to consent to electronic delivery of future proxy materials, supporting environmental initiatives.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Neuphoria Therapeutics
- Shareholders will vote virtually on director election, auditor ratification, and adjournment approval.NEUP
Proxy filing - Annual Meeting to vote on director election, auditor ratification, and adjournment authorization.NEUP
Proxy filing - FY26 saw a sharp revenue drop, major restructuring, and a $5.4M goodwill impairment amid a pending merger.NEUP
Q4 2026 - All-share merger forms a Nasdaq-listed immunotherapy firm, backed by $89M in new financing.NEUP
Proxy filing - BNC210 advances in late-stage trials for anxiety and PTSD, with strong Merck-backed Alzheimer's program.NEUP
Corporate presentation - Key clinical and financial milestones achieved, with cash runway through Q2 2027.NEUP
Q4 2025 - Biotech seeks up to $100M for late-stage neuropsychiatric drug trials, leveraging ATM sales.NEUP
Registration filing - Biopharma seeks up to $100M for CNS drug trials, with $2M ATM, amid US redomicile and Nasdaq risks.NEUP
Registration filing - Net income surged on Merck milestone; BNC210 Phase 3 data expected Q3 2025, cash runway into 2027.NEUP
Q3 2025